NCT02821182已完成2 期
A Phase II Trial of Stereotactic Body Radiotherapy With Concurrent Anti-PD1 Treatment in Metastatic Melanoma.
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 2
- 主要终点
- Efficacy
研究概览
简要总结
We hypothesize that combining anti-PD1 treatment with radiotherapy might result in improved clinical response rates and PFS compared to anti-PD1 treatment in monotherapy.
The current phase II trial aims at exploring the suggested benefits of the combination and aims to improve local and distant tumour responses by exploiting the pro-immunogenic effects of radiotherapy in addition to anti-PD1 treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Before patient registration, written informed consent must be given according to ICH/GCP, and national/local regulations.
- •Histologically confirmed diagnosis of melanoma
- •At least 3 extracranial measurable metastatic lesions per RECIST v1.
- •All radiology studies must be performed within 28 days prior to registration
- •First line anti-PD1 treatment.
- •Karnofsky Performance status > 60
- •Age 18 years or older
- •Female participants of childbearing potential must be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study treatment
- •Female participants who are breastfeeding or plan to breastfeed should be instructed to discontinue nursing during treatment.
- •Male participants must agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study treatment
- •Demonstrate adequate organ function defined as the following:
- •AST and ALT ≤2.5 X ULN or ≤5 X ULN with liver metastases
- •Serum total bilirubin ≤1.5 X ULN or direct bilirubin ≤ULN for patient with total bilirubin level >1.5 ULN
- •Serum creatinine ≤1.5 X ULN
- •Absolute neutrophil count >1,000 /mcL
- •Platelets >75,000 /mcL
- •Hemoglobin >9 g/dL or > 5.6 mmol/L
- •No history of active autoimmune disease requiring systemic treatment within the past 3 months or documented history of clinically severe autoimmune disease, or syndrome that requires systemic steroids or immunosuppressive agents
- •Prior malignancy: Subjects who have had another malignancy should be disease-free for 5 years, or should have a history of completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma
- •No evidence of interstitial lung disease
- •No uncontrolled central nervous metastases and/or carcinomatous meningitis.
- •No prior radiotherapy interfering with SBRT.
- •No concomitant therapy with IL-2, interferon, other immunotherapy regimens, chemotherapy, immunosuppressive agent or chronic use of systemic corticosteroids.
- •No active infection requiring systemic therapy
- •No known history of human immunodeficiency virus (HIV)
- •No known active Hepatitis B or Hepatitis C
- •Did not receive a live vaccine within 30 days prior to start of study treatment
- •No mental condition rendering the patient unable to understand the nature, scope and possible consequences of the study
- •Patient not unlikely to comply with the protocol; i.e. uncooperative attitude, inability to return for follow-up visits, and unlikely to complete the study
排除标准
- 未提供
结局指标
主要结局
Efficacy
时间窗: 12 weeks
Objective responses will be measured using RECIST v1.1. Objective responses will be defined as the number of patients with complete or partial responses as best response during follow-up.
次要结局
- Immunologic responses(12 weeks)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Stereotactic Radiotherapy and Anti-PD1 Antibody (Pembrolizumab) for Oligometastatic Renal TumoursRenal Cell CarcinomaNCT02855203Peter MacCallum Cancer Centre, Australia30
招募中
2 期
COmbination of Radiotherapy With Anti-PD-1 Antibody for unREseCtable Biliary Tract CancerBiliary Tract CancerRadiotherapyImmunotherapyNCT03898895Sun Yat-sen University36
已完成
不适用
Stereotactic Body Radiotherapy and Radiofrequency Ablation for Lung Tumors Near Central AirwaysLung CancerNCT01051037Jonsson Comprehensive Cancer Center17
Unknown
2 期
Combination of Radiation Therapy and Anti-PD-1 Antibody in Treating Patients With Pancreatic CancerPancreatic CancerNCT03374293Shixiu Wu21
已完成
2 期
Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal CancerEsophageal NeoplasmsEsophageal DiseasesEsophageal Squamous Cell CarcinomaNCT03187314Hangzhou Cancer Hospital25